| Abstract | AMD3100 is a drug capable of mobilizing peripheral blood stem cells (PBSCs) in donors and in cancer patients as a single agent or in combination with granulocyte-colony-stimulating factor (G-CSF). We initiated a phase II study of 11 refractory or relapsed non-Hodgkin's lymphoma (NHL) patients, receiving 16 microg/kg daily of G-CSF for 4 days followed by 240 microg/kg of AMD3100 given subcutaneously on a new schedule of 9-10 h before apheresis collection on day 5. Our aims were to assess the effect of AMD3100 on the mobilization of CD34+ cells, dendritic cells (DCs) and lymphoma cells. Administration of G-CSF and AMD3100 were continued daily until >or=2 x 10(6) CD34+ cells/kg were collected. Adequate collection of the target of CD34+ cells was achieved in all but 1 patient within 2 days, and 10/11 patients were transplanted within 2 months. All transplanted patients engrafted with a mean of 10 and 12 days for neutrophils and platelets, respectively. Addition of AMD3100 to G-CSF resulted with >2.5-fold increase in CD34+ cells/microl (p = 0.0001) and in a >2-fold increase in pDC1 and pDC2 cells/microl (p = 0.003). Adverse events related to AMD3100 were minimal. AMD3100 was generally safe and improved PBSC and DC cell mobilization with no apparent contamination of lymphoma cells. |
| Authors | Yair Gazitt, Cesar O Freytes, Cagla Akay, Karin Badel, Gary Calandra
(Affiliation: The University of Texas Health Science Center at San Antonio and Audie L Murphy Memorial Veterans Hospital, San Antonio, TX 78284, USA. gazitt at uthscsa.edu)
|
| Journal | Stem cells and development
(Stem Cells Dev)
Vol. 16
Issue 4
Pg. 657-66
(Aug 2007)
ISSN: 1547-3287 United States |
| PMID | 17784839
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Antigens, CD
- Antigens, CD34
- Heterocyclic Compounds
- Receptors, CXCR4
- Granulocyte Colony-Stimulating Factor
- JM 3100
|
| Topics |
- Adolescent
- Adult
- Aged
- Antigens, CD
(blood)
- Antigens, CD34
(blood)
- Dendritic Cells
(drug effects, physiology)
- Granulocyte Colony-Stimulating Factor
(pharmacology)
- Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cells
(drug effects, physiology)
- Heterocyclic Compounds
(pharmacology)
- Humans
- Lymphoma, Non-Hodgkin
(blood, pathology, therapy)
- Middle Aged
- Neutrophils
(transplantation)
- Patient Selection
- Receptors, CXCR4
(antagonists & inhibitors)
- Recurrence
- Tissue Preservation
(methods)
- Transplantation Conditioning
- Treatment Outcome
|
